Article
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity.
All News
Article
A population based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis
Article
I recently attended a fascinating lecture by Dr. Anisha Dua on progress in the diagnosis and treatment of large-vessel vasculitis, with a focus on giant cell arteritis (GCA) and Takayasu's arteritis. She opened with what felt like the most honest “state of the union” slide you can show a room full of rheumatologists: steroid burden is still enormous.
Dr. John Cush
Tweet
CDC study of Death certificate data showed that btw 2018–2023, there were 14,936 #SLE deaths (43% w/ SLE as the underlying cause). Mortality rate per million: females 5.97 > males 1.16, blacks 10.7. Causes of death:heart disease (0.93), cancer (0.56), COVID-19 (0.51). https://t.co/qTe6O66wRO
Dr. John Cush
Tweet
Cross-sectional study of Joint hypermobility (JH) in 256 young adults (75% female) found JH in 42%, females w/ signif. higher Beighton scores. 88% had chronic MSK pain; 38% had acute MSK pain. MSK pain was signif higher in students with mild JH (BS 4–6/9 pts; P < 0.009) https://t.co/QZwJ9zHfEj
Dr. John Cush
Tweet
BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi? Find out in the RheumNow poster hall with data from the latest real-world study of long-term RA remission. Sponsored by AbbVieMedical Affairs + Health Impact. https://t.co/PPYVfz3tuC https://t.co/Boq8V3qqFp
Dr. John Cush
Tweet
US Epidemiologic survey data from NHANES gout prevalence is incr. in RA pts vs controls (10.3% vs. 4.8%, P < 0.001), increasing trend over time. RA is as an independent risk factor for gout (OR: 2.67), strongest in SNRA. Evidence for the converse may not be as strong. https://t.co/VzDcJ2hTKw
Dr. John Cush
Tweet
Equivalent Healthcare Outcomes by Nurses and Physicians
With increasing demand for health services in an aging population, serving complex patients with comorbidities, and increasing healthcare costs, the question of whether nurses can substitute for physicians was addressed by https://t.co/nKsFn7pUgw
Dr. John Cush
Tweet
OA & Exercise? Metanalysis of 5 reviews (n=8631) & 28 trials (n=4360) show little or no proof that exercise benefits OA. Exercise has small, short-term effects vs placebo & no-treatment for knee OA pain. Moderate evidence of no effects in hip, & small effects in hand OA. https://t.co/ycLGNlP8Sf
Dr. John Cush
Tweet
The prevalence of Systemic lupus erythematosus (SLE) in Australia is 26,788 (16,294 certain, 10,494 uncertain cases). Betw 2010-2022 incidence was 77-127/100,000 (certain cases). About half had received SLE care in an outpatient setting. Australia is 1/13 the population of USA https://t.co/n1sbFNPRbn
Dr. John Cush
Tweet
“Common sense is the measure of the possible; it is composed of experience and prevision; it is calculation applied to life”
- Henri Frederic Amiel
Dr. John Cush
Tweet
Full read review of JAK inhibitors. JAK inhibitors have a reasonably rapid onset of action and a short half-life, which facilitates management of any adverse effects. The half-life of Tofacitinib, Baricitinib & Upadacitinib is 3 hrs, 13 hrs. & 9-14hrs. https://t.co/C9t2SQ3Juq
Dr. John Cush
Tweet
Epidemiology of Dry Eye Autoimmune Disease
Rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung https://t.co/Z8ZBGmqT93
Dr. John Cush
Tweet
3 Months of Romosozumab in Postmenopausal Osteoporosis
A report in The Lancet Diabetes & Endocrinology suggested that 3 months of romosozumab (ROMO) followed by denosumab is as effective at increasing hip bone mineral density (BMD) as the standard 12-month course. https://t.co/HPM7DdRFBM
Dr. John Cush
Tweet
Early vs Delayed Belimumab in Lupus
An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost-effectiveness and clinical utility of early BEL initiation in active lupus patients. https://t.co/7unHZhR6Dd
Dr. John Cush
Tweet
Nice simple overview of SCLERITIS. https://t.co/BOgZK8y4Qq https://t.co/P0dLtA3nKy
Dr. John Cush
Tweet
Antimitochondrial antibodies (AMA)in systemic sclerosis? Retro study of 165 SSc pts (20% diffuse, 33% ILD, 7% PAH); 51% centromere AB+; 29% topoisomerase I+, 12% RNA polymerase III+)-- 22% AMA-positive: assoc w/ GI vascular dz(OR 13.3), gastric antral vascular ectasia (OR 8) & https://t.co/FRhn9qIfOW
Dr. John Cush
Tweet
GLP-1s are known to improved knee OA. Using a mouse OA model w/ obesity, semaglutide yielded less pain, osteophytes & had strong chondroprotective effects, fia a wt loss-independent way. Changing from glycolysis to oxidative phosphorylation resulted in cartilage restoration. https://t.co/8zs34ys9o9
Dr. John Cush
Tweet
What did you miss at RheumNow Live 2026?
Our Poster Hall features new data across:
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Lupus Nephritis
• Vasculitis
• Polymyalgia Rheumatica
• Axial Spondyloarthritis
From Phase III trials to real-world evidence, these https://t.co/nuXGUdmwon
Dr. John Cush
Tweet
Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://t.co/cXTQ2TWyHZ
